(MedPage Today) — The FDA approved the first formulation of bevacizumab specifically for the treatment of neovascular (wet) age-related macular degeneration (nAMD), Outlook Therapeutics announced on Friday.
The approval of bevacizumab-vikg (Lytenava…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
